% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schossig:267552,
      author       = {P. Schossig and E. Coskun$^*$ and R. Arsenic and D. Horst
                      and J. Sehouli and E. Bergmann and N. Andresen and C. Sigler
                      and A. Busse$^*$ and U. Keller$^*$ and S. Ochsenreither$^*$},
      title        = {{T}arget {S}election for {T}-{C}ell {T}herapy in
                      {E}pithelial {O}varian {C}ancer: {S}ystematic
                      {P}rioritization of {S}elf-{A}ntigens.},
      journal      = {International journal of molecular sciences},
      volume       = {24},
      number       = {3},
      issn         = {1422-0067},
      address      = {Basel},
      publisher    = {Molecular Diversity Preservation International},
      reportid     = {DKFZ-2023-00330},
      pages        = {2292},
      year         = {2023},
      abstract     = {Adoptive T cell-receptor therapy (ACT) could represent a
                      promising approach in the targeted treatment of epithelial
                      ovarian cancer (EOC). However, the identification of
                      suitable tumor-associated antigens (TAAs) as targets is
                      challenging. We identified and prioritized TAAs for ACT and
                      other immunotherapeutic interventions in EOC. A
                      comprehensive list of pre-described TAAs was created and
                      candidates were prioritized, using predefined weighted
                      criteria. Highly ranked TAAs were immunohistochemically
                      stained in a tissue microarray of 58 EOC samples to identify
                      associations of TAA expression with grade, stage, response
                      to platinum, and prognosis. Preselection based on expression
                      data resulted in 38 TAAs, which were prioritized. Along with
                      already published Cyclin A1, the TAAs KIF20A, CT45, and LY6K
                      emerged as most promising targets, with high expression in
                      EOC samples and several identified peptides in ligandome
                      analysis. Expression of these TAAs showed prognostic
                      relevance independent of molecular subtypes. By using a
                      systematic vetting algorithm, we identified KIF20A, CT45,
                      and LY6K to be promising candidates for immunotherapy in
                      EOC. Results are supported by IHC and HLA-ligandome data.
                      The described method might be helpful for the prioritization
                      of TAAs in other tumor entities.},
      keywords     = {CT45 (Other) / Cyclin A1 (Other) / KIF20A (Other) / LY6K
                      (Other) / cytotoxic T lymphocytes (Other) / immunotherapy
                      (Other) / ovarian cancer (Other) / tumor associated antigen
                      (Other)},
      cin          = {BE01},
      ddc          = {540},
      cid          = {I:(DE-He78)BE01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36768616},
      doi          = {10.3390/ijms24032292},
      url          = {https://inrepo02.dkfz.de/record/267552},
}